参考文献
[1]
MillerKD, GodingSA, OrtizAP, et al.
Cancer statistics for hispanics/latinos, 2018[J].
CA Cancer J Clin,
2018,
4.
.
[2]
陈万青，李贺，孙可欣，等.
2014年中国恶性肿瘤发病和死亡分析[J].
中华肿瘤杂志，
2018,
40(
1)：
5-
13.
.
ChenWQ, LiH, SunKX, et al. Report of cancer incidence and mortality in China, 2014[J]. Chin J Oncol, 2018, 40(1)：5-13. .
[3]
ZengH, ZhengR, GuoY, et al.
Cancer survival in China, 2003-2005: a population-based study[J].
Int J Cancer,
2015,
136(
8)：
1921-
1930.
.
[4]
National Lung Screening Trial Research Team,
ChurchTR, BlackWC, et al.
Results of initial low-dose computed tomographic screening for lung cancer[J].
N Engl J Med,
2013,
368(
21)：
1980-
1991.
.
[5]
van KlaverenRJ, OudkerkM, ProkopM, et al.
Management of lung nodules detected by volume CT scanning[J].
N Engl J Med,
2009,
361(
23)：
2221-
2229.
.
[6]
WilleMM, DirksenA, AshrafH, et al.
Results of the randomized danish lung cancer screening trial with focus on high-risk profiling[J].
Am J Respir Crit Care Med,
2016,
193(
5)：
542-
551.
.
[7]
PastorinoU, RossiM, RosatoV, et al.
Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial[J].
Eur J Cancer Prev,
2012,
21(
3)：
308-
315.
.
[8]
FieldJK, DuffySW, BaldwinDR, et al.
The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer[J].
Health Technol Assess,
2016,
20(
40)：
1-
146.
.
[9]
BeckerN, MotschE, GrossML, et al.
Randomized study on early detection of lung cancer with MSCT in Germany: study design and results of the first screening round[J].
J Cancer Res Clin Oncol,
2012，
138(
9)：
1475-
1486.
.
[10]
Lopes PegnaA, PicozziG, MascalchiM, et al.
Design, recruitment and baseline results of the ITALUNG trial for lung cancer screening with low-dose CT[J].
Lung Cancer,
2009,
64(
1)：
34-
40.
.
[11]
InfanteM, LutmanFR, CavutoS, et al.
Lung cancer screening with spiral CT: baseline results of the randomized DANTE trial[J].
Lung Cancer,
2008，
59(
3)：
355-
363.
.
[12]
YangW, QianF, TengJ, et al.
Community-based lung cancer screening with low-dose CT in China: Results of the baseline screening[J].
Lung Cancer,
2018,
117：
20-
26.
.
[13]
PekarskyY, ZanesiN, PalamarchukA, et al.
FHIT: from gene discovery to cancer treatment and prevention[J].
Lancet Oncol,
2002,
3(
12)：
748-
754.
[14]
DollR, HillAB.
Smoking and carcinoma of the lung; preliminary report[J].
Br Med J,
1950,
2(
4682)：
739-
748.
[15]
DollR.
Atmospheric pollution and lung cancer[J].
Environ Health Perspect,
1978,
22：
23-
31.
.
[16]
PopeCA, DockeryDW, SchwartzJ.
Review of epidemiological evidence of health effects of particulate air pollution[J].
Inhalation Toxicol,
2008,
7(
1)：
1-
18.
[17]
LanQ, ChapmanRS, SchreinemachersDM, et al.
Household stove improvement and risk of lung cancer in Xuanwei, China[J].
J Natl Cancer Inst,
2002,
94(
11)：
826-
835.
[18]
王长利.
肺癌[M].
北京：
科学技术文献出版社，
2009：
24.
WangCL. Lung cancer[M]．Beijing: Science and technology literature press, 2009：24.
[19]
NitadoriJ, InoueM, IwasakiM, et al.
Association between lung cancer incidence and family history of lung cancer: data from a large-scale population-based cohort study, the JPHC study[J].
Chest,
2006,
130(
4)：
968-
975.
.
[20]
ChenW, ZhengR, BaadePD, et al.
Cancer statistics in China, 2015[J].
CA Cancer J Clin,
2016,
66(
2)：
115-
132.
.
[21]
储大同.
肺癌[M].
北京：
北京大学医学出版社，
2007：
8.
ChuDT. Lung cancer[M]. Beijing：Peking University medical press, 2007：8.
[22]
HydeL, HydeCI.
Clinical manifestations of lung cancer[J].
Chest,
1974,
65(
3)：
299-
306.
[23]
王长利.
肺癌[M].
北京：
科学技术文献出版社，
2009：
59.
WangCL. Lung cancer[M]. Beijing：Science and technology literature press, 2009：59.
[24]
储大同.
肺癌[M].
北京：
北京大学医学出版社，
2007：
122.
ChuDT. Lung cancer[M]. Beijing: Peking University medical press, 2007：122.
[25]
CarneyDN, MarangosPJ, IhdeDC, et al.
Serum neuron-specific enolase：a marker for disease extent and response to therapy of small-cell lung cancer[J].
Lancet,
1982,
1(
8272)：
583-
585.
[26]
PaoneG, De AngelisG, MunnoR, et al.
Discriminant analysis on small cell lung cancer and non-small cell lung cancer by means of NSE and CYFRA-21.1[J].
Eur Respir J,
1995,
8(
7)：
1136-
1140.
[27]
HatzakisKD, FroudarakisME, BourosD, et al.
Prognostic value of serum tumor markers in patients with lung cancer[J].
Respiration,
2002,
69(
1)：
25-
29.
.
[28]
LamyPJ, GrenierJ, KramarA, et al.
Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer[J].
Lung Cancer,
2000,
29(
3)：
197-
203.
[29]
TakeuchiS, NonakaM, KadokuraM, et al.
Prognostic significance of serum squamous cell carcinoma antigen in surgically treated lung cancer[J].
Ann Thorac Cardiovasc Surg,
2003,
9(
2)：
98-
104.
[30]
BarakV, GoikeH, PanaretakisKW, et al.
Clinical utility of cytokeratins as tumor markers[J].
Clin Biochem,
2004,
37(
7)：
529-
540.
.
[31]
StieberP, DienemannH, HasholznerU, et al.
Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS) as tumour markers in lung cancer[J].
Eur J Clin Chem Clin Biochem,
1993,
31(
10)：
689-
694.
[32]
ChewaskulyongB, TanyakulP, TantraworasinA.
Serum CYFRA 21-1 and CEA level as a predicting marker for advanced non-small cell lung cancer[J].
J Thorac Oncol,
2017，
12(
1):
S834-
S835.
[33]
DouglasE, EllaA, ScottL, et al.
Non-small cell lung cancer. version Ⅰ. 2018[EB/OL].
National Comprehensive Cancer Network, Inc.
2017 [
2017-06-23].
https://www.nccn.org.
[34]
TravisWD, BrambillaE, BurkeAP, et al.
WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart.
Lyon:
IARC Press，
2015.
[35]
TravisWD, BrambillaE, BurkeAP, et al.
Introduction to the 2015 World Health Organization Classification of tumors of the lung, pleura, thymus, and heart[J].
J Thorac Oncol,
2015,
10(
9)：
1240-
1242.
.
[36]
TravisWD, BrambillaE, NicholsonAG, et al.
The 2015 World Health Organization Classification of lung tumors: impact of genetic，clinical and radiologic advances since the 2004 classification[J].
J Thorac Oncol,
2015,
10(
9)：
1243-
1260.
.
[37]
TravisWD, BrambillaE, Rami-PortaR, et al.
Visceral pleural invasion: pathologic criteria and use of elastic stains: proposal for the 7th edition of the TNM classification for lung cancer[J].
J Thorac Oncol,
2008,
3(
12)：
1384-
1390.
.
[38]
TravisWD.
Advances in neuroendocrine lung tumors[J].
Ann Oncol,
2010，
21
Suppl 7：
vii65-
71.
.
[39]
PelosiG, RindiG, TravisWD, et al.
Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice[J].
J Thorac Oncol,
2014,
9(
3)：
273-
284.
.
[40]
PelosiG, RodriguezJ, VialeG, et al.
Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients[J].
Am J Surg Pathol,
2005,
29(
2)：
179-
187.
[41]
FabbriA, CossaM, SonzogniA, et al.
Thymus neuroendocrine tumors with CTNNB1 gene mutations, disarrayed β-catenin expression, and dual intra-tumor Ki-67 labeling index compartmentalization challenge the concept of secondary high-grade neuroendocrine tumor: a paradigm shift[J].
Virchows Arch,
2017,
471(
1)：
31-
47.
.
[42]
NonakaD.
A study of ΔNp63 expression in lung non-small cell carcinomas[J].
Am J Surg Pathol,
2012,
36(
6)：
895-
899.
.
[43]
ButnorKJ, BeasleyMB, CaglePT, et al.
Protocol for the examination of specimens from patients with primary non-small cell carcinoma, small cell carcinoma, or carcinoid tumor of the lung[J].
Arch Pathol Lab Med,
2009,
133(
10)：
1552-
1559.
.
[44]
KalemkerianGP, NarulaN, KennedyEB, et al.
Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update[J].
J Clin Oncol,
2018,
36(
9)：
911-
919.
.
[45]
LindemanNI, CaglePT, AisnerDL, et al.
Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the college of American pathologists, the international association for the study of lung cancer, and the Association for molecular pathology[J].
J Thorac Oncol,
2018,
13(
3)：
323-
358.
.
[46]
EllisonG, ZhuG, MoulisA, et al.
EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples[J].
J Clin Pathol,
2013,
66(
2)：
79-
89.
.
[47]
MokTS, WuYL, ThongprasertS, et al.
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J].
N Engl J Med,
2009,
361(
10)：
947-
957.
.
[48]
KrisMG, JohnsonBE, BerryLD, et al.
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs[J].
JAMA,
2014,
311(
19)：
1998-
2006.
.
[49]
SacherAG, DahlbergSE, HengJ, et al.
Association between younger age and targetable genomic alterations and prognosis in non-small-cell lung cancer[J].
JAMA Oncol,
2016,
2(
3)：
313-
320.
.
[50]
BarlesiF, MazieresJ, MerlioJP, et al.
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup(IFCT)[J].
Lancet,
2016,
387(
10026)：
1415-
1426.
.
[51]
PaoW, GirardN.
New driver mutations in non-small-cell lung cancer[J].
Lancet Oncol,
2011，
12(
2)：
175-
180.
.
[52]
GerberDE, GandhiL, CostaDB.
Management and future directions in non-small cell lung cancer with known activating mutations[J].
Am Soc Clin Oncol Educ Book,
2014：
e353-
365.
.
[53]
McLeer-FlorinA, Moro-SibilotD, MelisA, et al.
Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study[J].
J Thorac Oncol,
2012,
7(
2)：
348-
354.
.
[54]
ShollLM, WeremowiczS, GraySW, et al.
Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas[J].
J Thorac Oncol,
2013,
8(
3)：
322-
328.
.
[55]
ParkHS, LeeJK, KimDW, et al.
Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients[J].
Lung Cancer,
2012,
77(
2)：
288-
292.
.
[56]
ToKF, TongJH, YeungKS, et al.
Detection of ALK rearrangement by immunohistochemistry in lung adenocarcinoma and the identification of a novel EML4-ALK variant[J].
J Thorac Oncol,
2013,
8(
7)：
883-
891.
.
[57]
BlackhallFH, PetersS, BubendorfL, et al.
Prevalence and clinical outcomes for patients with ALK-positive resected stage Ⅰ to Ⅲ adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project[J].
J Clin Oncol,
2014,
32(
25)：
2780-
2787.
.
[58]
MazièresJ, ZalcmanG, CrinòL, et al.
Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort[J].
J Clin Oncol,
2015,
33(
9)：
992-
999.
.
[59]
ShawAT, OuSH, BangYJ, et al.
Crizotinib in ROS1-rearranged non-small-cell lung cancer[J].
N Engl J Med,
2014,
371(
21)：
1963-
1971.
.
[60]
CaiW, LiX, SuC, et al.
ROS1 fusions in Chinese patients with non-small-cell lung cancer[J].
Ann Oncol,
2013,
24(
7)：
1822-
1827.
.
[61]
ShollLM, SunH, ButaneyM, et al.
ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas[J].
Am J Surg Pathol,
2013,
37(
9)：
1441-
1449.
.
[62]
YoshidaA, TsutaK, WakaiS, et al.
Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers[J].
Mod Pathol,
2014,
27(
5)：
711-
720.
.
[63]
BoyleTA, MasagoK, EllisonKE, et al.
ROS1 immunohistochemistry among major genotypes of non-small-cell lung cancer[J].
Clin Lung Cancer,
2015,
16(
2)：
106-
111.
.
[64]
JenningsLJ, ArcilaME, CorlessC, et al.
Guidelines for validation of next-generation sequencing-based oncology panels: a joint consensus recommendation of the association for molecular pathology and college of American pathologists[J].
J Mol Diagn,
2017,
19(
3)：
341-
365.
.
[65]
EndrisV, PenzelR, WarthA, et al.
Molecular diagnostic profiling of lung cancer specimens with a semiconductor-based massive parallel sequencing approach: feasibility, costs, and performance compared with conventional sequencing[J].
J Mol Diagn,
2013,
15(
6)：
765-
775.
.
[66]
HeadSR, KomoriHK, LaMereSA, et al.
Library construction for next-generation sequencing: overviews and challenges[J].
Biotechniques,
2014,
56(
2)：
61-64, 66, 68,
.
.
[67]
ShollLM, AisnerDL, AllenTC, et al.
Programmed death ligand-1 immunohistochemistry: a new challenge for pathologists: a perspective from members of the pulmonary pathology society[J].
Arch Pathol Lab Med,
2016,
140(
4)：
341-
344.
.
[68]
RittmeyerA, BarlesiF, WaterkampD, et al.
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial[J].
Lancet,
2017,
389(
10066)：
255-
265.
.
[69]
HerbstRS, BaasP, KimDW, et al.
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial[J].
Lancet,
2016，
387(
10027)：
1540-
1550.
.
[70]
BorghaeiH, Paz-AresL, HornL, et al.
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J].
N Engl J Med,
2015，
373(
17)：
1627-
1639.
.
[71]
DudnikE, PeledN, NechushtanH, et al.
BRAF mutant lung cancer: programmed death ligand 1 expression, tumor mutational burden, microsatellite instability status, and response to immune check-point inhibitors[J].
J Thorac Oncol,
2018,
13(
8)：
1128-
1137.
.
[72]
GoodmanAM, KatoS, BazhenovaL, et al.
Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers[J].
Mol Cancer Ther,
2017,
16(
11)：
2598-
2608.
.
[73]
AurisicchioL, PalloccaM, CilibertoG, et al.
The perfect personalized cancer therapy: cancer vaccines against neoantigens[J].
J Exp Clin Cancer Res,
2018,
37(
1)：
86.
.
[74]
GinsbergRJ, RubinsteinLV.
Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group[J].
Ann Thorac Surg,
1995,
60(
3)：
615-
623.
[75]
VeluswamyRR, EzerN, MhangoG, et al.
Limited resection versus lobectomy for older patients with early-stage lung cancer: impact of histology[J].
J Clin Oncol,
2015,
33(
30)：
3447-
3453.
.
[76]
PagèsPB, MordantP, RenaudS, et al.
Sleeve lobectomy may provide better outcomes than pneumonectomy for non-small cell lung cancer. A decade in a nationwide study[J].
J Thorac Cardiovasc Surg,
2017,
153(
1)：
184-
195.e3.
.
[77]
StephensN, RiceD, CorreaA, et al.
Thoracoscopic lobectomy is associated with improved short-term and equivalent oncological outcomes compared with open lobectomy for clinical stage I non-small-cell lung cancer: a propensity-matched analysis of 963 cases[J].
Eur J Cardiothorac Surg,
2014,
46(
4)：
607-
613.
.
[78]
BalduyckB, HendriksJ, LauwersP, et al.
Quality of life after lung cancer surgery: a prospective pilot study comparing bronchial sleeve lobectomy with pneumonectomy[J].
J Thorac Oncol,
2008,
3(
6)：
604-
608.
.
[79]
MaZ, DongA, FanJ, et al.
Does sleeve lobectomy concomitant with or without pulmonary artery reconstruction (double sleeve) have favorable results for non-small cell lung cancer compared with pneumonectomy? A meta-analysis[J].
Eur J Cardiothorac Surg,
2007,
32(
1)：
20-
28.
.
[80]
ShiW, ZhangW, SunH, et al.
Sleeve lobectomy versus pneumonectomy for non-small cell lung cancer: a meta-analysis[J].
World J Surg Oncol,
2012,
10：
265.
.
[81]
KoikeT, KitaharaA, SatoS, et al.
Lobectomy versus segmentectomy in radiologically pure solid small-sized non-small cell lung cancer[J].
Ann Thorac Surg,
2016,
101(
4)：
1354-
1360.
.
[82]
BlasbergJD, PassHI, DoningtonJS.
Sublobar resection: a movement from the Lung Cancer Study Group[J].
J Thorac Oncol,
2010,
5(
10)：
1583-
1593.
[83]
NakamuraK, SajiH, NakajimaR, et al.
A phase Ⅲ randomized trial of lobectomy versus limited resection for small-sized peripheral non-small cell lung cancer (JCOG0802/WJOG4607L)[J].
Jpn J Clin Oncol,
2010,
40(
3)：
271-
274.
.
[84]
PetrellaF, SpaggiariL.
The smaller the better: a new concept in thoracic surgery？[J].
Lancet Oncol,
2016,
17(
6)：
699-
700.
.
[85]
ZhangW, WeiY, JiangH, et al.
Video-assisted thoracoscopic surgery versus thoracotomy lymph node dissection in clinical stage Ⅰ lung cancer: a meta-analysis and system review[J].
Ann Thorac Surg,
2016,
101(
6)：
2417-
2424.
.
[86]
BendixenM, JørgensenOD, KronborgC, et al.
Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: a randomised controlled trial[J].
Lancet Oncol,
2016,
17(
6)：
836-
844.
.
[87]
OsarogiagbonRU, DeckerPA, BallmanK, et al.
Survival implications of variation in the thoroughness of pathologic lymph node examination in American College of Surgeons Oncology Group Z0030 (Alliance)[J].
Ann Thorac Surg,
2016,
102(
2)：
363-
369.
.
[88]
Rami-PortaR, WittekindC, GoldstrawP.
Complete resection in lung cancer surgery: proposed definition[J].
Lung Cancer,
2005,
49(
1)：
25-
33.
.
[89]
DarlingGE, AllenMS, DeckerPA, et al.
Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial[J].
J Thorac Cardiovasc Surg,
2011,
141(
3)：
662-
670.
.
[90]
HowingtonJA, BlumMG, ChangAC, et al.
Treatment of stage Ⅰ and Ⅱnon-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines[J].
Chest,
2013,
143(
5
Suppl)：
e278S-
e313S.
.
[91]
SocinskiMA, EvansT, GettingerS, et al.
Treatment of stage Ⅳ non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines[J].
Chest,
2013，
143(
5
Suppl)：
e341S-
e368S.
.
[92]
VansteenkisteJ, De RuysscherD, EberhardtWE, et al.
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J].
Ann Oncol,
2013,
24
Suppl 6：
vi89-
98.
.
[93]
NSCLC Meta-analyses Collaborative Group,
ArriagadaR, AuperinA, et al.
Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data[J].
Lancet,
2010,
375(
9722)：
1267-
1277.
.
[94]
WakeleeHA, DahlbergSE, KellerSM, et al.
Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial[J].
Lancet Oncol,
2017，
18(
12)：
1610-
1623.
.
[95]
StraussGM, HerndonJE, MaddausMA, et al.
Adjuvant paclitaxel plus carboplatin compared with observation in stage ⅠB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups[J].
J Clin Oncol,
2008,
26(
31)：
5043-
5051.
.
[96]
ButtsCA, DingK, SeymourL, et al.
Randomized phase Ⅲ trial of vinorelbine plus cisplatin compared with observation in completely resected stage ⅠB and Ⅱ non-small-cell lung cancer: updated survival analysis of JBR-10[J].
J Clin Oncol,
2010,
28(
1)：
29-
34.
.
[97]
QianF, YangW, WangR, et al.
Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage ⅠB lung adenocarcinoma[J].
J Thorac Cardiovasc Surg,
2018,
155(
3)：
1227-
1235.e2.
.
[98]
BradleyJD, PaulusR, GrahamMV, et al.
Phase Ⅱ trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage Ⅱ and ⅢA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group: RTOG 9705[J].
J Clin Oncol,
2005,
23(
15)：
3480-
3487.
.
[99]
LallyBE, ZeltermanD, ColasantoJM, et al.
Postoperative radiotherapy for stage Ⅱ or Ⅲ non-small-cell lung cancer using the surveillance, epidemiology, and end results database[J].
J Clin Oncol,
2006,
24(
19)：
2998-
3006.
.
[100]
DouillardJY, RosellR, De LenaM, et al.
Impact of postoperative radiation therapy on survival in patients with complete resection and stage Ⅰ，Ⅱ，or ⅢA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial[J].
Int J Radiat Oncol Biol Phys,
2008,
72(
3)：
695-
701.
.
[101]
KrisMG, GasparLE, ChaftJE, et al.
Adjuvant systemic therapy and adjuvant radiation therapy for stage Ⅰ to ⅢA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update[J].
J Clin Oncol,
2017,
35(
25)：
2960-
2974.
.
[102]
GhiribelliC, VoltoliniL, PaladiniP, et al.
Treatment and survival after lung resection for non-small cell lung cancer in patients with microscopic residual disease at the bronchial stump[J].
Eur J Cardiothorac Surg,
1999,
16(
5)：
555-
559.
[103]
ParkHJ, ParkHS, ChaYJ, et al.
Efficacy of adjuvant chemotherapy for completely resected stage ⅠB non-small cell lung cancer: a retrospective study[J].
J Thorac Dis,
2018，
10(
4)：
2279-
2287.
.
[104]
WisniveskyJP, SmithCB, PackerS, et al.
Survival and risk of adverse events in older patients receiving postoperative adjuvant chemotherapy for resected stages Ⅱ-ⅢA lung cancer: observational cohort study[J].
BMJ,
2011,
343：
d4013.
.
[105]
ZhouM, LiT, LiuY, et al.
Concurrent paclitaxel-based chemo-radiotherapy for post-surgical microscopic residual tumor at the bronchial margin (R1 resection) in non-small-cell lung cancer[J].
BMC Cancer,
2015，
15：
36.
.
[106]
KozowerBD, LarnerJM, DetterbeckFC, et al.
Special treatment issues in non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines[J].
Chest,
2013,
143(
5
Suppl)：
e369S-
e399S.
.
[107]
LeventakosK, PeikertT, MidthunDE, et al.
Management of multifocal lung cancer: results of a Survey[J].
J Thorac Oncol,
2017,
12(
9)：
1398-
1402.
.
[108]
TanvetyanonT, FinleyDJ, FabianT, et al.
Prognostic factors for survival after complete resections of synchronous lung cancers in multiple lobes: pooled analysis based on individual patient data[J].
Ann Oncol,
2013,
24(
4)：
889-
894.
.
[109]
van TinterenH, HoekstraOS, SmitEF, et al.
Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial[J].
Lancet,
2002,
359(
9315)：
1388-
1393.
[110]
HerderGJ, KramerH, HoekstraOS, et al.
Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study[J].
J Clin Oncol,
2006,
24(
12)：
1800-
1806.
.
[111]
CerfolioRJ, BryantAS, OjhaB, et al.
Improving the inaccuracies of clinical staging of patients with NSCLC: a prospective trial[J].
Ann Thorac Surg,
2005,
80(
4)：
1207-
1214.
.
[112]
De LeynP, DoomsC, KuzdzalJ, et al.
Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer[J].
Eur J Cardiothorac Surg,
2014,
45(
5)：
787-
798.
.
[113]
SilvestriGA, GonzalezAV, JantzMA, et al.
Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines[J].
Chest,
2013,
143(
5
Suppl)：
e211S-
e250S.
.
[114]
DongX, QiuX, LiuQ, et al.
Endobronchial ultrasound-guided transbronchial needle aspiration in the mediastinal staging of non-small cell lung cancer: a meta-analysis[J].
Ann Thorac Surg,
2013,
96(
4)：
1502-
1507.
.
[115]
MicamesCG, McCroryDC, PaveyDA, et al.
Endoscopic ultrasound-guided fine-needle aspiration for non-small cell lung cancer staging: a systematic review and metaanalysis[J].
Chest,
2007,
131(
2)：
539-
548.
.
[116]
AnnemaJT, van MeerbeeckJP, RintoulRC, et al.
Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial[J].
JAMA,
2010,
304(
20)：
2245-
2252.
.
[117]
De LeynP, StroobantsS, De WeverW, et al.
Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage ⅢA-N2 non-small-cell lung cancer: a Leuven Lung Cancer Group Study[J].
J Clin Oncol,
2006,
24(
21)：
3333-
3339.
.
[118]
KimSY, KimJS, ParkHS, et al.
Screening of brain metastasis with limited magnetic resonance imaging (MRI): clinical implications of using limited brain MRI during initial staging for non-small cell lung cancer patients[J].
J Korean Med Sci,
2005,
20(
1)：
121-
126.
.
[119]
HendriksLE, BootsmaGP, de RuysscherDK, et al.
Screening for brain metastases in patients with stage Ⅲ non-small cell lung cancer: is there additive value of magnetic resonance imaging above a contrast-enhanced computed tomography of the brain？[J].
Lung Cancer,
2013,
80(
3)：
293-
297.
.
[120]
BrunelliA, CharlouxA, BolligerCT, et al.
ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)[J].
Eur Respir J,
2009,
34(
1)：
17-
41.
.
[121]
PignonJP, TribodetH, ScagliottiGV, et al.
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group[J].
J Clin Oncol,
2008,
26(
21)：
3552-
3559.
.
[122]
FiratS, ByhardtRW, GoreE.
Comorbidity and Karnofksy performance score are independent prognostic factors in stage Ⅲ non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group[J].
Int J Radiat Oncol Biol Phys,
2002,
54(
2)：
357-
364.
[123]
ColinetB, JacotW, BertrandD, et al.
A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson′s index[J].
Br J Cancer,
2005,
93(
10)：
1098-
1105.
.
[124]
CharlsonM, SzatrowskiTP, PetersonJ, et al.
Validation of a combined comorbidity index[J].
J Clin Epidemiol,
1994,
47(
11)：
1245-
1251.
[125]
EberhardtWE, De RuysscherD, WederW, et al.
2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage Ⅲ non-small-cell lung cancer[J].
Ann Oncol,
2015,
26(
8)：
1573-
1588.
.
[126]
BoffaDJ, HancockJG, YaoX, et al.
Now or later: evaluating the importance of chemotherapy timing in resectable stage Ⅲ(N2) lung cancer in the National Cancer Database[J].
Ann Thorac Surg,
2015,
99(
1)：
200-
208.
.
[127]
LimE, HarrisG, PatelA, et al.
Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials[J].
J Thorac Oncol,
2009,
4(
11)：
1380-
1388.
.
[128]
GrahamAN, ChanKJ, PastorinoU, et al.
Systematic nodal dissection in the intrathoracic staging of patients with non-small cell lung cancer[J].
J Thorac Cardiovasc Surg,
1999,
117(
2)：
246-
251.
.
[129]
De LeynP, LardinoisD, Van SchilPE, et al.
ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer[J].
Eur J Cardiothorac Surg,
2007,
32(
1)：
1-
8.
.
[130]
WederW, CollaudS, EberhardtWE, et al.
Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage Ⅲ non-small-cell lung cancer[J].
J Thorac Cardiovasc Surg,
2010,
139(
6)：
1424-
1430.
.
[131]
KimAW, BoffaDJ, WangZ, et al.
An analysis, systematic review, and meta-analysis of the perioperative mortality after neoadjuvant therapy and pneumonectomy for non-small cell lung cancer[J].
J Thorac Cardiovasc Surg,
2012,
143(
1)：
55-
63.
.
[132]
CurranWJ, PaulusR, LangerCJ, et al.
Sequential vs. concurrent chemoradiation for stage Ⅲ non-small cell lung cancer: randomized phase Ⅲ trial RTOG 9410[J].
J Natl Cancer Inst,
2011,
103(
19)：
1452-
1460.
.
[133]
AupérinA, Le PéchouxC, RollandE, et al.
Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer[J].
J Clin Oncol,
2010,
28(
13)：
2181-
2190.
.
[134]
RamnathN, DillingTJ, HarrisLJ, et al.
Treatment of stage Ⅲ non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines[J].
Chest,
2013,
143(
5
Suppl)：
e314S-
e340S.
.
[135]
BradleyJ, BaeK, ChoiN, et al.
A phase Ⅱ comparative study of gross tumor volume definition with or without PET/CT fusion in dosimetric planning for non-small-cell lung cancer (NSCLC): primary analysis of Radiation Therapy Oncology Group (RTOG) 0515[J].
Int J Radiat Oncol Biol Phys,
2012,
82(
1)：
435-
441.e1.
.
[136]
Sanuki-FujimotoN, SumiM, ItoY, et al.
Relation between elective nodal failure and irradiated volume in non-small-cell lung cancer (NSCLC) treated with radiotherapy using conventional fields and doses[J].
Radiother Oncol,
2009,
91(
3)：
433-
437.
.
[137]
KongFM, Ten HakenRK, SchipperM, et al.
Effect of midtreatment PET/CT-adapted radiation therapy with concurrent chemotherapy in patients with locally advanced non-small-cell lung cancer: a phase 2 clinical trial[J].
JAMA Oncol,
2017,
3(
10)：
1358-
1365.
.
[138]
MauguenA, Le PéchouxC, SaundersMI, et al.
Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis[J].
J Clin Oncol,
2012,
30(
22)：
2788-
2797.
.
[139]
BradleyJD, PaulusR, KomakiR, et al.
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage ⅢA or ⅢB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study[J].
Lancet Oncol,
2015,
16(
2)：
187-
199.
.
[140]
LiaoZX, KomakiRR, ThamesHD, et al.
Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy[J].
Int J Radiat Oncol Biol Phys,
2010,
76(
3)：
775-
781.
.
[141]
SejpalS, KomakiR, TsaoA, et al.
Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer[J].
Cancer,
2011,
117(
13)：
3004-
3013.
.
[142]
ChangJY, KomakiR, LuC, et al.
Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage Ⅲ nonsmall cell lung cancer[J].
Cancer,
2011,
117(
20)：
4707-
4713.
.
[143]
ChunSG, HuC, ChoyH, et al.
Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial[J].
J Clin Oncol,
2017,
35(
1)：
56-
62.
.
[144]
HannaN, NeubauerM, YiannoutsosC, et al.
Phase Ⅲ study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage Ⅲ non-small-cell lung cancer: the Hoosier Oncology Group and U．S. Oncology[J].
J Clin Oncol,
2008,
26(
35)：
5755-
5760.
.
[145]
WangL, WuS, OuG, et al.
Randomized phase Ⅱ study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage Ⅲ non-small cell lung cancer[J].
Lung Cancer,
2012,
77(
1)：
89-
96.
.
[146]
GovindanR, BogartJ, StinchcombeT, et al.
Randomized phase Ⅱ study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407[J].
J Clin Oncol,
2011,
29(
23)：
3120-
3125.
.
[147]
SenanS, BradeA, WangLH, et al.
PROCLAIM: randomized phase Ⅲ Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer[J].
J Clin Oncol,
2016,
34(
9)：
953-
962.
.
[148]
ChoyH, GerberDE, BradleyJD, et al.
Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage Ⅲ non-small cell lung cancer: a systematic review of completed and ongoing studies[J].
Lung Cancer,
2015,
87(
3)：
232-
240.
.
[149]
SauseW, KolesarP, TaylorSIV, et al.
Final results of phase Ⅲ trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group[J].
Chest,
2000,
117(
2)：
358-
364.
[150]
BelderbosJ, UitterhoeveL, van ZandwijkN, et al.
Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973)[J].
Eur J Cancer,
2007,
43(
1)：
114-
121.
.
[151]
DaweDE, ChristiansenD, SwaminathA, et al.
Chemoradiotherapy versus radiotherapy alone in elderly patients with stage Ⅲ non-small cell lung cancer: a systematic review and meta-analysis[J].
Lung Cancer,
2016,
99：
180-
185.
.
[152]
SigelK, LurslurchachaiL, BonomiM, et al.
Effectiveness of radiation therapy alone for elderly patients with unresected stage Ⅲ non-small cell lung cancer[J].
Lung Cancer,
2013,
82(
2)：
266-
270.
.
[153]
CardenalF, NadalE, JovéM, et al.
Concurrent systemic therapy with radiotherapy for the treatment of poor-risk patients with unresectable stage Ⅲ non-small-cell lung cancer: a review of the literature[J].
Ann Oncol,
2015,
26(
2)：
278-
288.
.
[154]
VokesEE, HerndonJE 2nd, KelleyMJ, et al.
Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage Ⅲ Non-small-cell lung cancer: Cancer and Leukemia Group B[J].
J Clin Oncol,
2007,
25(
13)：
1698-
1704.
.
[155]
SocinskiMA, BlackstockAW, BogartJA, et al.
Randomized phase Ⅱ trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage Ⅲ non-small-cell lung cancer: CALGB 30105[J].
J Clin Oncol,
2008,
26(
15)：
2457-
2463.
.
[156]
SauseWT, ScottC, TaylorS, et al.
Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase Ⅲ trial in regionally advanced, unresectable non-small-cell lung cancer[J].
J Natl Cancer Inst,
1995,
87(
3)：
198-
205.
[157]
TsujinoK, KurataT, YamamotoS, et al.
Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small-cell lung cancer? A pooled analysis of the literature[J].
J Thorac Oncol,
2013,
8(
9)：
1181-
1189.
.
[158]
InoueA, KobayashiK, MaemondoM, et al.
Updated overall survival results from a randomized phase Ⅲ trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)[J].
Ann Oncol,
2013,
24(
1)：
54-
59.
.
[159]
MitsudomiT, MoritaS, YatabeY, et al.
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial[J].
Lancet Oncol,
2010,
11(
2)：
121-
128.
.
[160]
ZhouC, WuYL, ChenG, et al.
Final overall survival results from a randomised, phase Ⅲ study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)[J].
Ann Oncol,
2015,
26(
9)：
1877-
1883.
.
[161]
ShiYK, WangL, HanBH, et al.
First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study[J].
Ann Oncol,
2017,
28(
10)：
2443-
2450.
.
[162]
SequistLV, YangJC, YamamotoN, et al.
Phase Ⅲ study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations[J].
J Clin Oncol,
2013,
31(
27)：
3327-
3334.
.
[163]
SoriaJC, OheY, VansteenkisteJ, et al.
Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer[J].
N Engl J Med,
2018,
378(
2)：
113-
125.
.
[164]
YangJC, SequistLV, GeaterSL, et al.
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6[J].
Lancet Oncol,
2015,
16(
7)：
830-
838.
.
[165]
ShawAT, KimDW, NakagawaK, et al.
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer[J].
N Engl J Med,
2013,
368(
25)：
2385-
2394.
.
[166]
SolomonBJ, MokT, KimDW, et al.
First-line crizotinib versus chemotherapy in ALK-positive lung cancer[J].
N Engl J Med,
2014,
371(
23)：
2167-
2177.
.
[167]
ScagliottiGV, KortsikC, DarkGG, et al.
Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase Ⅱ trial[J].
Clin Cancer Res,
2005,
11(
2
Pt 1)：
690-
696.
[168]
OheY, OhashiY, KubotaK, et al.
Randomized phase Ⅲ study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan[J].
Ann Oncol,
2007,
18(
2)：
317-
323.
.
[169]
ScagliottiGV, ParikhP, von PawelJ, et al.
Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer[J].
J Clin Oncol,
2008,
26(
21)：
3543-
3551.
.
[170]
FossellaF, PereiraJR, von PawelJ, et al.
Randomized, multinational, phase Ⅲ study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group[J].
J Clin Oncol,
2003,
21(
16)：
3016-
3024.
.
[171]
TanEH, SzczesnaA, KrzakowskiM, et al.
Randomized study of vinorelbine: gemcitabine versus vinorelbine: carboplatin in patients with advanced non-small cell lung cancer[J].
Lung Cancer,
2005,
49(
2)：
233-
240.
.
[172]
PujolJL, BretonJL, GervaisR, et al.
Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase Ⅲ study addressing the case for cisplatin[J].
Ann Oncol,
2005,
16(
4)：
602-
610.
.
[173]
SandlerA, GrayR, PerryMC, et al.
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer[J].
N Engl J Med,
2006,
355(
24)：
2542-
2550.
.
[174]
Paz-AresLG, de MarinisF, DediuM, et al.
PARAMOUNT: final overall survival results of the phase Ⅲ study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer[J].
J Clin Oncol,
2013,
31(
23)：
2895-
2902.
.
[175]
GridelliC, de MarinisF, ThomasM, et al.
Final efficacy and safety results of pemetrexed continuation maintenance therapy in the elderly from the PARAMOUNT phase Ⅲ study[J].
J Thorac Oncol,
2014,
9(
7)：
991-
997.
.
[176]
BrodowiczT, KrzakowskiM, ZwitterM, et al.
Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase Ⅲ trial[J].
Lung Cancer,
2006,
52(
2)：
155-
163.
.
[177]
PérolM, ChouaidC, PérolD, et al.
Randomized, phase Ⅲ study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer[J].
J Clin Oncol,
2012,
30(
28)：
3516-
3524.
.
[178]
KostyMP, WozniakAJ, JahanzebM, et al.
Effectiveness and safety of post-induction phase bevacizumab treatment for patients with non-small-cell lung cancer: results from the ARIES observational cohort study[J].
Target Oncol,
2015,
10(
4)：
509-
516.
.
[179]
CiuleanuT, BrodowiczT, ZielinskiC, et al.
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study[J].
Lancet,
2009，
374(
9699)：
1432-
1440.
.
[180]
ShukuyaT, YamanakaT, SetoT, et al.
Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial[J].
Lancet Oncol,
2015,
16(
16)：
1630-
1638.
.
[181]
HanB, TjulandinS, HagiwaraK, et al.
EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: the IGNITE study[J].
Lung Cancer,
2017,
113：
37-
44.
.
[182]
ParkK, YuCJ, KimSW, et al.
First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer: the ASPIRATION study[J].
JAMA Oncol,
2016,
2(
3)：
305-
312.
.
[183]
WeickhardtAJ, ScheierB, BurkeJM, et al.
Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer[J].
J Thorac Oncol,
2012,
7(
12)：
1807-
1814.
.
[184]
ConfortiF, CataniaC, ToffalorioF, et al.
EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lung[J].
Lung Cancer,
2013,
81(
3)：
440-
444.
.
[185]
ShukuyaT, TakahashiT, NaitoT, et al.
Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure[J].
Lung Cancer,
2011,
74(
3)：
457-
461.
.
[186]
YuHA, SimaCS, HuangJ, et al.
Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors[J].
J Thorac Oncol,
2013,
8(
3)：
346-
351.
.
[187]
MokTS, WuY-L1, AhnM-J, et al.
Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer[J].
N Engl J Med,
2017,
376(
7)：
629-
640.
.
[188]
HanB, LiK, ZhaoY, et al.
Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase Ⅱ trial (ALTER0302)[J].
Br J Cancer,
2018,
118(
5)：
654-
661.
.
[189]
OuSH, JännePA, BartlettCH, et al.
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC[J].
Ann Oncol,
2014,
25(
2)：
415-
422.
.
[190]
ShawAT, VargheseAM, SolomonBJ, et al.
Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer[J].
Ann Oncol,
2013,
24(
1)：
59-
66.
.
[191]
LeeHY, AhnHK, JeongJY, et al.
Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer[J].
Lung Cancer,
2013,
79(
1)：
40-
45.
.
[192]
WuYL, LuS, ChengY, et al.
Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer (NSCLC): results of the phase 3 CheckMate 078 study [J].
Cancer Res,
2018,
78(
13
Suppl)：
.
[193]
ShepherdFA, DanceyJ, RamlauR, et al.
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy[J].
J Clin Oncol,
2000,
18(
10)：
2095-
2103.
.
[194]
HannaN, ShepherdFA, FossellaFV, et al.
Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy[J].
J Clin Oncol,
2004,
22(
9)：
1589-
1597.
.
[195]
BrahmerJ, ReckampKL, BaasP, et al.
Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer[J].
N Engl J Med,
2015,
373(
2)：
123-
135.
.
[196]
PatchellRA, TibbsPA, WalshJW, et al.
A randomized trial of surgery in the treatment of single metastases to the brain[J].
N Engl J Med,
1990,
322(
8)：
494-
500.
.
[197]
VechtCJ, Haaxma-ReicheH, NoordijkEM, et al.
Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery？[J].
Ann Neurol,
1993，
33(
6)：
583-
590.
.
[198]
NoordijkEM, VechtCJ, Haaxma-ReicheH, et al.
The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age[J].
Int J Radiat Oncol Biol Phys,
1994,
29(
4)：
711-
717.
[199]
RossiNP, ZavalaDC, VanGilderJC.
A combined surgical approach to non-oat-cell pulmonary carcinoma with single cerebral metastasis[J].
Respiration,
1987,
51(
3)：
170-
178.
.
[200]
SchuchertMJ, LuketichJD.
Solitary sites of metastatic disease in non-small cell lung cancer[J].
Curr Treat Options Oncol,
2003,
4(
1)：
65-
79.
[201]
YukselC, BozkurtM, YenigunBM, et al.
The outcome of bifocal surgical resection in non-small cell lung cancer with synchronous brain metastases: results of a single center retrospective study[J].
Thorac Cardiovasc Surg,
2014，
62(
7)：
605-
611.
.
[202]
SundaresanN, GalicichJH.
Surgical treatment of single brain metastases from non-small-cell lung cancer[J].
Cancer Invest,
1985,
3(
2)：
107-
113.
[203]
TorreM, BarbieriB, BeraE, et al.
Surgical therapy in lung cancer with single brain metastasis[J].
Eur J Cardiothorac Surg,
1988,
2(
5)：
336-
339.
[204]
BillingsJA, FerrisFD, MacdonaldN, et al.
The role of palliative care in the home in medical education: report from a national consensus Conference[J].
J Palliat Med,
2001,
4(
3)：
361-
371.
.
[205]
GranoneP, MargaritoraS, D′AndrilliA, et al.
Non-small cell lung cancer with single brain metastasis: the role of surgical treatment[J].
Eur J Cardiothorac Surg,
2001,
20(
2)：
361-
366.
[206]
AmbrogiV, ToniniG, MineoTC.
Prolonged survival after extracranial metastasectomy from synchronous resectable lung cancer[J].
Ann Surg Oncol,
2001,
8(
8)：
663-
666.
[207]
RazDJ, LanutiM, GaissertHC, et al.
Outcomes of patients with isolated adrenal metastasis from non-small cell lung carcinoma[J].
Ann Thorac Surg,
2011,
92(
5)：
1788-
1793.
.
[208]
PlönesT, Osei-AgyemangT, KrohnA, et al.
Surgical Treatment of Extrapulmonary Oligometastatic Non-small Cell Lung Cancer[J].
Indian J Surg,
2015,
77(
Suppl 2)：
216-
220.
.
[209]
XuQ, WangY, LiuH, et al.
Treatment outcome for patients with primary NSCLC and synchronous solitary metastasis[J].
Clin Transl Oncol,
2013,
15(
10)：
802-
809.
.
[210]
PorteH, SiatJ, GuibertB, et al.
Resection of adrenal metastases from non-small cell lung cancer: a multicenter study[J].
Ann Thorac Surg,
2001,
71(
3)：
981-
985.
[211]
MordantP, ArameA, De DominicisF, et al.
Which metastasis management allows long-term survival of synchronous solitary M1b non-small cell lung cancer？[J].
Eur J Cardiothorac Surg,
2012,
41(
3)：
617-
622.
.
[212]
CollenC, ChristianN, SchallierD, et al.
Phase Ⅱ study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients[J].
Ann Oncol,
2014,
25(
10)：
1954-
1959.
.
[213]
De RuysscherD, WandersR, van BaardwijkA, et al.
Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase Ⅱ trial (Nct01282450)[J].
J Thorac Oncol,
2012,
7(
10)：
1547-
1555.
.
[214]
IyengarP, KavanaghBD, WardakZ, et al.
Phase Ⅱ trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer[J].
J Clin Oncol,
2014,
32(
34)：
3824-
3830.
.
[215]
AoyamaH, TagoM, ShiratoH.
Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: secondary analysis of the JROSG 99-1 randomized clinical trial[J].
JAMA Oncol,
2015,
1(
4)：
457-
464.
.
[216]
DowneyRJ, NgKK, KrisMG, et al.
A phase Ⅱ trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis[J].
Lung Cancer,
2002,
38(
2)：
193-
197.
[217]
De PasTM, de BraudF, CatalanoG, et al.
Oligometastatic non-small cell lung cancer: a multidisciplinary approach in the positron emission tomographic scan era[J].
Ann Thorac Surg,
2007,
83(
1):
231-
234.
.
[218]
OuyangWW, SuSF, MaZ, et al.
Prognosis of non-small cell lung cancer patients with bone oligometastases treated concurrently with thoracic three-dimensional radiotherapy and chemotherapy[J].
Radiat Oncol,
2014,
9：
147.
.
[219]
GriffioenGH, ToguriD, DaheleM, et al.
Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors[J].
Lung Cancer,
2013,
82(
1)：
95-
102.220.
.
[220]
吴一龙，蒋国梁，廖美琳，等.
非小细胞肺癌孤立性转移处理共识[J].
循证医学，
2007,
7(
2)：
109-
111.
WuYL, JiangGL, LiaoML，et al. Chinese Consensus on Treatment of Single Metastasis from Non-Small Cell Lung Cancer[J]. The Journal of Evidence-Based Medicine，2007，7(2)：109-111. .
[221]
LadT, PiantadosiS, ThomasP，et al.
A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy[J].
Chest,
1994,
106(
6
Suppl)：
320S-
323S.
[222]
ShepherdFA, EvansWK, FeldR, et al.
Adjuvant chemotherapy following surgical resection for small-cell carcinoma of the lung[J].
J Clin Oncol,
1988,
6(
5)：
832-
838.
.
[223]
TsuchiyaR, SuzukiK, IchinoseY, et al.
Phase Ⅱ trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage Ⅰ-Ⅲa small cell lung cancer: the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101)[J].
J Thorac Cardiovasc Surg,
2005,
129(
5)：
977-
983.
.
[224]
SchreiberD, RineerJ, WeedonJ, et al.
Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated？[J].
Cancer,
2010,
116(
5)：
1350-
1357.
.
[225]
WongAT, RineerJ, SchwartzD, et al.
Assessing the impact of postoperative radiation therapy for completely resected limited-stage small cell lung cancer using the national cancer database[J].
J Thorac Oncol,
2016,
11(
2)：
242-
248.
.
[226]
AupérinA, ArriagadaR, PignonJP, et al.
Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group[J].
N Engl J Med,
1999,
341(
7)：
476-
484.
.
[227]
TakadaM, FukuokaM, KawaharaM, et al.
Phase Ⅲ study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104[J].
J Clin Oncol,
2002,
20(
14)：
3054-
3060.
.
[228]
TurrisiAT 3rd, KimK, BlumR, et al.
Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide[J].
N Engl J Med,
1999,
340(
4)：
265-
271.
.
[229]
SchildSE, BonnerJA, ShanahanTG, et al.
Long-term results of a phase Ⅲ trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer[J].
Int J Radiat Oncol Biol Phys,
2004,
59(
4)：
943-
951.
.
[230]
ChoiNC, HerndonJE, RosenmanJ, et al.
Phase Ⅰ study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer[J].
J Clin Oncol,
1998,
16(
11)：
3528-
3536.
.
[231]
MillerKL, MarksLB, SibleyGS, et al.
Routine use of approximately 60 Gy once-daily thoracic irradiation for patients with limited-stage small-cell lung cancer[J].
Int J Radiat Oncol Biol Phys,
2003,
56(
2)：
355-
359.
[232]
RoofKS, FidiasP, LynchTJ, et al.
Radiation dose escalation in limited-stage small-cell lung cancer[J].
Int J Radiat Oncol Biol Phys,
2003,
57(
3)：
701-
708.
[233]
BogartJA, HerndonJE 2nd, LyssAP, et al.
70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808[J].
Int J Radiat Oncol Biol Phys,
2004,
59(
2)：
460-
468.
.
[234]
SundstrømS, BremnesRM, KaasaS, et al.
Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase Ⅲ trial with 5 years′ follow-up[J].
J Clin Oncol,
2002,
20(
24)：
4665-
4672.
.
[235]
RossiA, Di MaioM, ChiodiniP, et al.
Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data[J].
J Clin Oncol,
2012,
30(
14)：
1692-
1698.
.
[236]
FriedDB, MorrisDE, PooleC, et al.
Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer[J].
J Clin Oncol,
2004,
22(
23)：
4837-
4845.
.
[237]
StinchcombeTE, GoreEM.
Limited-stage small cell lung cancer: current chemoradiotherapy treatment paradigms[J].
Oncologist,
2010,
15(
2)：
187-
195.
.
[238]
SpigelDR, TownleyPM, WaterhouseDM, et al.
Randomized phase Ⅱ study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial[J].
J Clin Oncol,
2011,
29(
16)：
2215-
2222.
.
[239]
OkamotoH, WatanabeK, NishiwakiY, et al.
Phase Ⅱ study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer[J].
J Clin Oncol,
1999,
17(
11)：
3540-
3545.
.
[240]
NodaK, NishiwakiY, KawaharaM, et al.
Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer[J].
N Engl J Med,
2002,
346(
2)：
85-
91.
.
[241]
ChengY, FanY, LiuXQ, et al.
A randomized, multicenter phase Ⅲ study of lobaplatin/etoposide versus cisplatin/etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer and circulating tumor cells (CTCs) as an exploratory biomarker[J].
J Clin Oncol,
2014,
32(
15s
suppl):
.
[242]
ChengY, LiuXQ, FanY, et al.
Circulating tumor cell counts/change for outcome prediction in patients with extensive-stage small-cell lung cancer[J].
Future Oncol,
2016,
12(
6)：
789-
799.
.
[243]
JeremicB, ShibamotoY, NikolicN, et al.
Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study[J].
J Clin Oncol,
1999,
17(
7)：
2092-
2099.
.
[244]
YeeD, ButtsC, ReimanA, et al.
Clinical trial of post-chemotherapy consolidation thoracic radiotherapy for extensive-stage small cell lung cancer[J].
Radiother Oncol,
2012,
102(
2)：
234-
238.
.
[245]
SlotmanBJ, van TinterenH, PraagJO, et al.
Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial[J].
Lancet,
2015,
385(
9962)：
36-
42.
.
[246]
JeremicB, CasasF, WangL, et al.
Radiochemotherapy in extensive disease small cell lung cancer ED-SCLC[J].
Front Radiat Ther Oncol,
2010,
42：
180-
186.
.
[247]
SlotmanB, Faivre-FinnC, KramerG, et al.
Prophylactic cranial irradiation in extensive small-cell lung cancer[J].
N Engl J Med,
2007,
357(
7)：
664-
672.
.
[248]
TakahashiT, YamanakaT, SetoT, et al.
Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial[J].
Lancet Oncol,
2017,
18(
5)：
663-
671.
.
[249]
MickeP, FaldumA, MetzT, et al.
Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer: what limits limited disease？[J].
Lung Cancer,
2002,
37(
3)：
271-
276.
[250]
Le PéchouxC, DunantA, SenanS, et al.
Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial[J].
Lancet Oncol,
2009,
10(
5)：
467-
474.
.
[251]
SlotmanBJ, MauerME, BottomleyA, et al.
Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase Ⅲ randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups[J].
J Clin Oncol,
2009,
27(
1)：
78-
84.
.
[252]
von PawelJ, SchillerJH, ShepherdFA, et al.
Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer[J].
J Clin Oncol,
1999,
17(
2)：
658-
667.
.
[253]
O′BrienME, CiuleanuTE, TsekovH, et al.
Phase Ⅲ trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer[J].
J Clin Oncol,
2006,
24(
34)：
5441-
5447.
.
[254]
EckardtJR, von PawelJ, PujolJL, et al.
Phase Ⅲ study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer[J].
J Clin Oncol,
2007,
25(
15)：
2086-
2092.
.
[255]
DerksJL, HendriksLE, BuikhuisenWA, et al.
Clinical features of large cell neuroendocrine carcinoma: a population-based overview[J].
Eur Respir J,
2016，
47(
2)：
615-
624.
.
[256]
MastersGA, TeminS, AzzoliCG, et al.
Systemic therapy for stage Ⅳnon-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update[J].
J Clin Oncol,
2015,
33(
30)：
3488-
3515.
.
[257]
AbsengerG, TerzicJ, BezanA.
ASCO update: lung cancer[J].
Memo,
2017,
10(
4)：
224-
227.
.
[258]
ColtHG, MurguSD, KorstRJ, et al.
Follow-up and surveillance of the patient with lung cancer after curative-intent therapy: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines[J].
Chest,
2013,
143(
5
Suppl)：
e437S-
e454S.
.
[259]
LouF, HuangJ, SimaCS, et al.
Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance[J].
J Thorac Cardiovasc Surg,
2013,
145(
1)：
75-
82.
.
[260]
CrabtreeTD, PuriV, ChenSB, et al.
Does the method of radiologic surveillance affect survival after resection of stage I non-small cell lung cancer？[J].
J Thorac Cardiovasc Surg,
2015,
149(
1)：
45-52, 53.e1- e3.
.
[261]
BackhusLM, FarjahF, LiangCK, et al.
Imaging surveillance and survival for surgically resected non-small-cell lung cancer[J].
J Surg Res,
2016，
200(
1)：
171-
176.
.
[262]
WesteelV, LebitasyMP, MercierM, et al.
IFCT-0302 trial: randomised study comparing two follow-up schedules in completely resected non-small cell lung cancer [J].
Rev Mal Respir,
2007,
24(
5)：
645-
652.
[263]
TakenakaD, OhnoY, KoyamaH, et al.
Integrated FDG-PET/CT vs. standard radiological examinations: comparison of capability for assessment of postoperative recurrence in non-small cell lung cancer patients[J].
Eur J Radiol,
2010，
74(
3)：
458-
464.
.
[264]
CuaronJ, DunphyM, RimnerA.
Role of FDG-PET scans in staging, response assessment, and follow-up care for non-small cell lung cancer[J].
Front Oncol,
2013,
2：
208.
.
[265]
MamonHJ, YeapBY, JännePA, et al.
High risk of brain metastases in surgically staged ⅢA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation[J].
J Clin Oncol,
2005,
23(
7)：
1530-
1537.
.
[266]
PostmusPE, KerrKM, OudkerkM, et al.
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J].
Ann Oncol,
2017,
28(
suppl_4)：
iv1-
1iv21.
.
[267]
HuY, McMurryTL, IsbellJM, et al.
Readmission after lung cancer resection is associated with a 6-fold increase in 90-day postoperative mortality[J].
J Thorac Cardiovasc Surg,
2014,
148(
5)：
2261-
2267.e1.
.
[268]
PezziCM, MallinK, MendezAS, et al.
Ninety-day mortality after resection for lung cancer is nearly double 30-day mortality[J].
J Thorac Cardiovasc Surg,
2014,
148(
5)：
2269-
2277.
.
[269]
Janssen-HeijnenML, van ErningFN, De RuysscherDK, et al.
Variation in causes of death in patients with non-small cell lung cancer according to stage and time since diagnosis[J].
Ann Oncol,
2015，
26(
5)：
902-
907.
.
[270]
JohnsonBE.
Second lung cancers in patients after treatment for an initial lung cancer[J].
J Natl Cancer Inst,
1998,
90(
18)：
1335-
1345.
[271]
RipleyRT, McMillanRR, SimaCS, et al.
Second primary lung cancers: smokers versus nonsmokers after resection of stage Ⅰ lung adenocarcinoma[J].
Ann Thorac Surg,
2014,
98(
3)：
968-
974.
.
[272]
HamajiM, AllenMS, CassiviSD, et al.
Surgical treatment of metachronous second primary lung cancer after complete resection of non-small cell lung cancer[J].
J Thorac Cardiovasc Surg,
2013,
145(
3)：
683-
691.
.
[273]
SprattDE, WuAJ, AdeseyeV, et al.
Recurrence patterns and second primary lung cancers after stereotactic body radiation therapy for early-stage non-small-cell lung cancer: implications for surveillance[J].
Clin Lung Cancer,
2016,
17(
3)：
177-
183.e2.
.
[274]
HuangK, SenthiS, PalmaDA, et al.
High-risk CT features for detection of local recurrence after stereotactic ablative radiotherapy for lung cancer[J].
Radiother Oncol,
2013,
109(
1)：
51-
57.
.
[275]
PeulenH, MantelF, GuckenbergerM, et al.
Validation of high-risk computed tomography features for detection of local recurrence after stereotactic body radiation therapy for early-stage non-small cell lung cancer[J].
Int J Radiat Oncol Biol Phys,
2016,
96(
1)：
134-
141.
.
[276]
NeriS, TakahashiY, TerashiT, et al.
Surgical treatment of local recurrence after stereotactic body radiotherapy for primary and metastatic lung cancers[J].
J Thorac Oncol,
2010,
5(
12)：
2003-
2007.
.
[277]
HamamotoY, KataokaM, YamashitaM, et al.
Lung-cancer related chest events detected by periodical follow-up CT after stereotactic body radiotherapy for stage Ⅰ primary lung cancer: retrospective analysis of incidence of lung-cancer related chest events and outcomes of salvage treatment[J].
Jpn J Radiol,
2012,
30(
8)：
671-
675.
.
[278]
TairaN, KawabataT, IchiT, et al.
Salvage operation for late recurrence after stereotactic body radiotherapy for lung cancer: two patients with no viable cancer cells[J].
Ann Thorac Surg,
2014,
97(
6)：
2167-
2171.
.
[279]
HamajiM, ChenF, MatsuoY, et al.
Treatment and prognosis of isolated local relapse after stereotactic body radiotherapy for clinical stage Ⅰnon-small-cell lung cancer: importance of salvage surgery[J].
J Thorac Oncol,
2015,
10(
11)：
1616-
1624.
.
[280]
DickhoffC, DaheleM, PaulMA, et al.
Salvage surgery for locoregional recurrence or persistent tumor after high dose chemoradiotherapy for locally advanced non-small cell lung cancer[J].
Lung Cancer,
2016,
94：
108-
113.
.
[281]
VerstegenNE, MaatAP, LagerwaardFJ, et al.
Salvage surgery for local failures after stereotactic ablative radiotherapy for early stage non-small cell lung cancer[J].
Radiat Oncol,
2016,
11(
1)：
131.
.
_files/cscd_logo.png){kind=logo}
_files/wanfangdata_logo.png){kind=logo}
_files/weixin.gif)
_files/sinaminiblog.gif)
_files/youdaonote.gif)
_files/twitter.gif)
_files/facebook.gif)
_files/gplus.gif)
_files/evernote.gif)
_files/reddit.gif)
_files/diigo.gif)
_files/linkedin.gif)
_files/instapaper.gif)
_files/itieba.gif)
_files/friendfeed.gif)
_files/douban.gif)
_files/clipboard.gif)
_files/favorite.gif)
_files/gmail.gif)
_files/poco.gif)
_files/readitlater.gif)